Santhera Pharmaceuticals Holding AG

LSE:0QN1 Stock Report

Market Cap: CHF 170.5m

Santhera Pharmaceuticals Holding Valuation

Is 0QN1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QN1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CHF 219.87
Fair Value
93.6% undervalued intrinsic discount
2
Number of Analysts

Below Fair Value: 0QN1 (CHF14.16) is trading below our estimate of fair value (CHF219.87)

Significantly Below Fair Value: 0QN1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QN1?

Key metric: As 0QN1 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0QN1. This is calculated by dividing 0QN1's market cap by their current earnings.
What is 0QN1's PE Ratio?
PE Ratio2.7x
EarningsCHF 62.86m
Market CapCHF 170.45m

Price to Earnings Ratio vs Peers

How does 0QN1's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QN1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average60.4x
BVXP Bioventix
21.9xn/aUK£177.5m
GNS Genus
123.4x31.5%UK£974.8m
HVO hVIVO
7.1x-29.6%UK£123.8m
CGEN Compugen
89x-52.9%US$142.4m
0QN1 Santhera Pharmaceuticals Holding
2.7x30.3%CHF 170.5m

Price-To-Earnings vs Peers: 0QN1 is good value based on its Price-To-Earnings Ratio (2.7x) compared to the peer average (60.4x).

Price to Earnings Ratio vs Industry

How does 0QN1's PE Ratio compare vs other companies in the European Biotechs Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.28.8x35.9%
0QN1 Santhera Pharmaceuticals Holding
 2.7x30.3%US$186.80m
0QN1 2.7xIndustry Avg. 28.8xNo. of Companies5PE020406080100+
6 CompaniesEstimated GrowthMarket Cap
Industry Avg.28.8x35.9%
0QN1 Santhera Pharmaceuticals Holding
 2.7x30.3%US$186.80m
No more companies

Price-To-Earnings vs Industry: 0QN1 is good value based on its Price-To-Earnings Ratio (2.7x) compared to the European Biotechs industry average (28.8x).

Price to Earnings Ratio vs Fair Ratio

What is 0QN1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QN1 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio2.7x
Fair PE Ratio22.4x

Price-To-Earnings vs Fair Ratio: 0QN1 is good value based on its Price-To-Earnings Ratio (2.7x) compared to the estimated Fair Price-To-Earnings Ratio (22.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QN1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 14.16
CHF 32.00
+126.0%
21.9%CHF 39.00CHF 25.00n/a2
Jan ’26CHF 14.10
CHF 32.00
+127.0%
21.9%CHF 39.00CHF 25.00n/a2
Dec ’25CHF 8.15
CHF 32.00
+292.6%
21.9%CHF 39.00CHF 25.00n/a2
Nov ’25CHF 8.69
CHF 32.00
+268.2%
21.9%CHF 39.00CHF 25.00n/a2
Oct ’25CHF 9.30
CHF 32.00
+244.1%
21.9%CHF 39.00CHF 25.00n/a2
Sep ’25CHF 9.05
CHF 34.50
+281.2%
13.0%CHF 39.00CHF 30.00n/a2
Aug ’25CHF 9.30
CHF 34.50
+271.0%
13.0%CHF 39.00CHF 30.00n/a2
Jul ’25CHF 8.63
CHF 34.50
+299.8%
13.0%CHF 39.00CHF 30.00n/a2
Jan ’25CHF 9.81
CHF 71.00
+623.8%
57.7%CHF 112.00CHF 30.00CHF 14.102
Dec ’24CHF 9.21
CHF 70.00
+659.7%
60.0%CHF 112.00CHF 28.00CHF 8.152
Nov ’24CHF 10.83
CHF 70.00
+546.3%
60.0%CHF 112.00CHF 28.00CHF 8.692
Oct ’24CHF 8.34
CHF 68.00
+715.3%
64.7%CHF 112.00CHF 24.00CHF 9.302
Sep ’24CHF 8.78
CHF 68.00
+674.3%
64.7%CHF 112.00CHF 24.00CHF 9.052
Aug ’24CHF 8.52
CHF 68.00
+698.5%
64.7%CHF 112.00CHF 24.00CHF 9.302
Feb ’24CHF 8.79
CHF 88.00
+901.1%
54.5%CHF 136.00CHF 40.00CHF 9.352
Jan ’24CHF 14.02
CHF 88.00
+527.7%
54.5%CHF 136.00CHF 40.00CHF 9.812
Analyst Price Target
Consensus Narrative from 2 Analysts
CHF 32.18
Fair Value
56.0% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 03:36
End of Day Share Price 2025/01/09 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Santhera Pharmaceuticals Holding AG is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maurizio BernasconiBank am Bellevue
Silvia SchanzBank Vontobel AG
Barbora BlahaCredit Suisse